Correlative Analysis
tumor
DISEASE, TUMOR
We evaluated 11 serum sample pairs for HGF prior to initiation of treatment on days 1 and 1 of cycle 2. Of the 11 pairs, 9 were evaluable for response at MTD. There was no association between C1D1 HGF values and best response (Fourteen of the patients had sufficient samples from pre-treatment tissue biopsies for immunohistochemistry analysis to characterize pre-treatment histology and assess c-Met pathway activation. Of the 14 patients, 3 received ficlatuzumab at 10 mg/kg and 11 received ficlatuzumab at 20 mg/kg. Interrogation for markers of c-Met pathway activation included analysis of HGF, c-Met, p-Met, p-ERK, p-Akt, and p-S6K expression by immunohistochemistry (IHC) in tumor cells. Among 9 patients with available response data, H-score for p-Met was associated with disease response rate (The correlation between p-Met and clinical response.